Viewing Study NCT00085904

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:51 PM
Ignite Modification Date: 2026-01-26 @ 6:01 AM
Study NCT ID: NCT00085904
Status: COMPLETED
Last Update Posted: 2008-10-13
First Post: 2004-06-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumor Cancer View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced cancer View
None IL-18 View
None repeat dosing View
None Phase 1 View
None pharmacokinetics View
None oncology View